TY - JOUR
T1 - SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularisation in a rat model of Retinopathy of Prematurity
AU - Gammons, Melissa V
AU - Dick, Andrew D
AU - Harper, Steven J
AU - Bates, David O
PY - 2013/6/11
Y1 - 2013/6/11
N2 - PURPOSE. We tested the hypothesis that recombinant human VEGF-A165b and the serine arginine protein kinase (SRPK) inhibitor, SRPIN340, which controls splicing of the VEGF-A pre-mRNA, prevent neovascularisation in a rodent model of retinopathy of prematurity (ROP). METHODS. In the 50/10 oxygen-induced retinopathy (50/10 OIR) model that exposes newborn rats to repeated cycles of 24 h of 50% oxygen alternating with 24 h of 10% oxygen, pups received intraocular injections of SRPIN340, vehicle, VEGF165b, anti-VEGF antibody or saline. Wholemounts of retinas were prepared for isolectin immunohistochemistry, and pre-retinal or intravitreal neovascularisation (PRNV) determined by clock hour analysis. RESULTS. The anti-VEGF antibody (p
AB - PURPOSE. We tested the hypothesis that recombinant human VEGF-A165b and the serine arginine protein kinase (SRPK) inhibitor, SRPIN340, which controls splicing of the VEGF-A pre-mRNA, prevent neovascularisation in a rodent model of retinopathy of prematurity (ROP). METHODS. In the 50/10 oxygen-induced retinopathy (50/10 OIR) model that exposes newborn rats to repeated cycles of 24 h of 50% oxygen alternating with 24 h of 10% oxygen, pups received intraocular injections of SRPIN340, vehicle, VEGF165b, anti-VEGF antibody or saline. Wholemounts of retinas were prepared for isolectin immunohistochemistry, and pre-retinal or intravitreal neovascularisation (PRNV) determined by clock hour analysis. RESULTS. The anti-VEGF antibody (p
U2 - 10.1167/iovs.13-11634
DO - 10.1167/iovs.13-11634
M3 - Article (Academic Journal)
C2 - 23761094
JO - Investigative Ophthalmology and Visual Science
JF - Investigative Ophthalmology and Visual Science
SN - 0146-0404
ER -